NormOxys

About NormOxys

NormOxys, Inc. operates as a clinical-stage biotechnology firm focused on creating a novel class of small molecule drugs. Founded in 2003 by Professor Claude Nicolau, with the underlying science advanced by Nobel Laureate Professor Jean-Marie Lehn, the company is headquartered in Wellesley, Massachusetts. The company's core technology revolves around developing polyol phosphate-based small molecules, referred to as "oxyrens" (oxygen release enhancers), designed to improve the delivery of oxygen to diseased tissues characterized by oxygen deficiency (hypoxia).

The primary business of NormOxys is the research and development of these specialized drugs to treat a range of significant medical conditions. The company's main product candidate, OXY111A, functions as an allosteric modulator of hemoglobin. This means it binds to hemoglobin within red blood cells, altering its structure to release more oxygen than it normally would. By increasing the oxygen supply to hypoxic tissues, OXY111A aims to restore them to normal oxygenation levels. This mechanism has potential therapeutic applications in oncology and cardiovascular diseases, such as chronic heart failure. For cancer treatment, the approach is to normalize the oxygen levels within tumors, which can counteract survival mechanisms and make them more susceptible to apoptosis (programmed cell death).

The company's business model is typical for a development-stage biotechnology entity, centering on advancing its proprietary drug candidates through the rigorous phases of clinical trials to establish safety and efficacy. Revenue generation is anticipated through future licensing agreements or partnerships with larger pharmaceutical companies upon successful proof-of-concept data from human trials. To fund its operations, NormOxys has engaged in venture capital financing, securing significant capital in several rounds. Notably, a Series B financing round in 2010 raised $17.5 million, led by Care Capital with participation from existing investor Index Ventures, bringing the total capital raised at that time to $30 million. This funding was allocated to advance OXY111A into clinical development after receiving clearance for an Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA).